Ascletis Pharma Inc. (OTCMKTS:ASCLF) Short Interest Up 146.1% in January

Ascletis Pharma Inc. (OTCMKTS:ASCLF) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 456,545 shares, an increase of 146.1% from the December 31st total of 185,545 shares. Based on an average trading volume of 3,676 shares, the short-interest ratio is presently 124.2 days. Based on an average trading volume of 3,676 shares, the short-interest ratio is presently 124.2 days.

Ascletis Pharma Price Performance

Shares of ASCLF stock remained flat at $1.76 during trading hours on Thursday. The business’s 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $1.54. Ascletis Pharma has a 12 month low of $0.62 and a 12 month high of $2.29.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).